Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maine for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maine only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maine (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brian Haney (NPI 1285830554)

Field	Value
Entity Type	Individual
Organization	Brian Haney
Address	105 Topsham Fair Mall Rd Unit 1
City	Topsham
State	ME
ZIP	04086
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 25, 2007

Payer Source	Total Paid
Medicare	$1.2M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology Physician by taxonomy and the code mix is dominated by oncology drug infusions and associated E/M visits. The single largest revenue line is J9271 (pembrolizumab) at $834.2K (69.1% of Medicare revenue), supported by chemotherapy administration codes such as 96413 and add–on codes 96417/96415, which together indicate an infusion-centered oncology practice delivering systemic cancer therapy. The presence of supportive care drug codes (J0897 denosumab, J0881 darbepoetin alfa) and frequent lab panels (80053, 85025) further supports a full-service outpatient oncology infusion model.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 83.0% of the provider's total Medicare revenue, signaling heavy dependence on a very small set of high-cost oncology drugs and a single payer. J9271 alone contributes $834.2K (69.1%), with J0897 at $120.8K (10.0%) and 99214 at $46.4K (3.8%), so changes in utilization or reimbursement for these codes would materially affect the provider’s Medicare revenue. Given this concentration, payer or formulary shifts affecting pembrolizumab or denosumab usage could disproportionately impact revenue.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is reported as $1.2M while Medicaid revenue is listed as none, so the practice appears to have no Medicaid billing on file. This creates concentrated exposure to Medicare policy and reimbursement trends and suggests the provider either treats primarily Medicare beneficiaries or bills chemotherapy services predominantly under Medicare. Analysts should treat Medicaid impact as negligible in the current billing record.

Competitive standing on the top drug is above median but not dominant nationally: J9271 is listed at ranks #429 of 1841 providers nationally (76th percentile) and is characterized in the source as "typical, unremarkable volume for this code." That percentile indicates the provider treats more pembrolizumab patients than the median provider but is not among the highest-volume national centers. Similarly, J0897 ranks #2129 of 10057 (79th percentile) and is also described as "typical, unremarkable volume for this code," reflecting solid but not market-leading denosumab provision.

Office visit utilization and intensity align with outpatient oncology management: 99214 accounts for $46.4K (3.8% of Medicare revenue) across 516 claims with an average paid/claim of $90, and 99215/99213 are present at lower shares. The 90th-percentile national rank for 99214 (ranks #46452 of 479517; labeled "typical, unremarkable volume for this code") suggests the provider performs an above-median number of moderate-complexity established-patient visits, consistent with follow-up and treatment management in oncology. This supports a model of ongoing patient follow-up tied to infusion schedules rather than episodic consult-only work.

Operational detail: per-claim paid amounts on the top drug codes are relatively low compared with their revenue impact, reflecting high claim volume rather than high unit price. J9271 shows $43 avg paid/claim across 19.4K claims and J0897 shows $19 avg paid/claim across 6.4K claims, meaning revenue is driven by large claim counts for these high-cost therapies rather than by high per-claim reimbursements. Analysts should interpret the revenue concentration as volume-driven throughput of expensive biologic therapies.

Lab and ancillary services appear as supportive revenue lines rather than primary drivers: comprehensive metabolic panel 80053 ($8K, rank #2046 of 26416, 92th percentile) and CBC 85025 ($7.5K, rank #2543 of 32833, 92th percentile) are present at relatively high national percentiles but represent small shares of total revenue. These high-percentile lab ranks—with the source labeling them "typical, unremarkable volume for this code"—are consistent with routine monitoring practices accompanying systemic oncology therapy and do not materially diversify the provider’s revenue base.

The provider has established tenure in the Medicare system, with NPI enumeration dated 2007-06-25 (~19 years ago), which supports a stable, long-running outpatient oncology practice. Given the long enrollment period combined with concentrated Medicare-only billing, continuity of operations appears likely, but the business remains highly exposed to utilization patterns for a narrow set of oncology drugs. Review of referral patterns and any affiliations would be the next step to assess capacity and growth potential given the existing infusion-centered profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

58 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,400	$40	$834.2K
J0897	Injection, denosumab, 1 mg	6,360	$20	$120.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	520	$90	$46.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	15,200	$1	$30.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	330	$90	$30.2K
J1439	Injection, ferric carboxymaltose, 1 mg	22,500	$1	$22.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	160	$130	$20.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	270	$60	$16.7K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	50	$310	$15.6K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	100	$140	$13.7K

Showing 1–10 of 58

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maine Distribution

Brian Haney — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maine

Full comparison — all codes billed, vs. state median

58 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	16,450	$40	$699.2K
J0897	5	20	2,730	$20	$86.4K
J0881	4	10	15,200	$1	$47K
J1439	7	10	24,750	$1	$32.2K
J9217	5	10	120	$130	$27.9K
96413	6	30	170	$100	$20.6K
J1454	6	10	60	$340	$18.3K
99214	25	2,500	70	$70	$7.2K
96401	4	10	80	$50	$6.1K
96365	10	30	90	$50	$5.6K

Showing 1–10 of 58

Related Providers

Other providers that share a Tax Identification Number (TIN) with Brian Haney, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Hospital	ME	General Acute Care Hospital	$0	$35.5M
Can Ilyas	ME	Hematology & Oncology Physician	$3.2M	$0
David Benton	ME	Hematology & Oncology Physician	$2.6M	$0
Matthew Dugan	ME	Hematology & Oncology Physician	$1.8M	$0
John Winters	ME	Hematology & Oncology Physician	$1.5M	$0
Maine Center For Cancer Medicine & Blood Disorders, P.A.	ME	Hematology & Oncology Physician	$0	$1.5M
Christian Thomas	ME	Hematology & Oncology Physician	$1.5M	$0
Devon Evans	ME	Hematology & Oncology Physician	$1.5M	$0
Yoko Fukuda	NH	Hematology & Oncology Physician	$945K	$0
Jonathan Proulx	NH	Hematology (Internal Medicine) Physician	$725.4K	$0

Nearby Providers

Other providers in the same ZIP code as Brian Haney, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Chonko Occupational Therapy, LLC	ME	Occupational Therapist	$0	$772.2K
Julia Moukharskaya	ME	Hematology & Oncology Physician	$519.1K	$0
Greater Brunswick Physical Therapy P.A.	ME	Physical Therapist	$0	$511.7K
Town Of Topsham	ME	Land Ambulance	$126.7K	$205.4K
Jose Ventura	ME	Family Medicine Physician	$50.9K	$197.8K
Michael Davis	ME	Family Nurse Practitioner	$109.4K	$0
Cvs State Capital LLC	ME	Pharmacy	$70.5K	$0
David Inger	ME	Family Medicine Physician	$36.6K	$0
Megan Hutcherson	ME	Pediatric Occupational Therapist	$33.7K	$0
Victoria Thieme	ME	Neuromusculoskeletal Medicine & OMM Physician	$24.3K	$7.4K

Brian Haney — Billing Profile & Reimbursement Data

Sign up for Brian Haney — Billing Profile & Reimbursement Data policy alerts

Brian Haney — Billing Profile & Reimbursement Data

Sign up for Brian Haney — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References